NCT06756295View on ClinicalTrials.gov

A Phase I/ II Study of Fragmented Autoantigen Stimulated T-cell-immunotherapy Combined with Radiotherapy (FAST-CR)

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

March 1, 2028

Conditions
Breast Cancer, Colorectal CancerMelanomaLung Cancer
Interventions
BIOLOGICAL

individualized tumor FAST vaccine combination (including adjuvant)

Using the patient's individual tumor tissue, an autologous FAST (Fragmented Autoantigen Stimulated T-cell Immunotherapy) vaccine is prepared.

All Listed Sponsors
collaborator

The University of Hong Kong-Shenzhen Hospital

OTHER

collaborator

Peking University

OTHER

lead

Fengming Kong

OTHER